Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Slides:



Advertisements
Similar presentations
Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.
Advertisements

National Patient Safety Goal 3E:
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
Volume 359: November 6, 2008 Number 19November 6, 2008.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Venous Thromboembolism
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
HICKMAN CATHETER Thrombotic complications associated with venous access devic Thrombotic complications associated with venous access devices Occlusion.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
DVT Prevention and Anticoagulant Management
VTE prevention and anticoagulation practice VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis Nurse RCHT.
The Anticoagulation Service at Salisbury District Hospital Nic McQuaid And Rachel Woodford Anticoagulation Nurse Practitioners.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
Risk Assessment for VTE. Which of the following best describes you?
Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic.
Postpartum period in women with systemic lupus erythematosus BY DR KH ELMIZADEH.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Outpatient DVT assessment & treatment Daniel Gilada.
Dr. Hadab A. Mohamed. BACKGROUND Temporary interruption Thrombotic risk Continuation Bleeding risk A great challenge, especially in the emergency setting.
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Venous thrombosis , why should I care ?
Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.
Venous Thromboembolism Prophylaxis for Medical Inpatients
By: Dr. Nalaka Gunawansa
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
Copyright © 2012 American Medical Association. All rights reserved.
Ortho Warfarin Dosing Protocol
Fatimah Al-Ani 1,2,. MD MRCP, Jose Maria Bastida Bermejo3,
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Thromboprophylaxis during labour and delivery
The Burden of Hospital-Associated Venous Thromboembolism
HICKMAN CATHETER. HICKMAN CATHETER Thrombotic complications associated with venous access devices Occlusion of lumen Fibrin sheath formation Venous.
Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y
Fibrillazione atriale
New Oral Anticoagulants and VTE Management
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 
Succinct Review of the New VTE Prevention and Management Guidelines
Cancer-Associated Thrombosis
by Alex C. Spyropoulos, and James D. Douketis
How I treat cancer-associated venous thromboembolism
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
Thrombophilia in pregnancy: Whom to screen, when to treat
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Presentation transcript:

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma

Anticoagulation Regimen Use unfractionated heparin or LMWH at a prophylactic dose for as long as the patient is on therapy

Patient With Renal Failure Use full-dose warfarin

Patient With a History of VTE If > 1 VTE evaluate for a possible thrombophilia; in more difficult cases seek a multidisciplinary consult

Bortezomib-based (IMiD-less) Regimens No need for prophylaxis unless there are additional risk factors

Relapse Setting Prophylaxis for Patients on Pomalidomide-based Therapy

IMiD-only Regimens No prophylaxis or use low-dose aspirin

Patient on IMiD-based Regimen Who Develops a DVT or PE Continue or stop therapy while increasing level of anticoagulation?

Patient Who Develops a Catheter-related Thrombosis Interrupt therapy while the patient is appropriately managed, then resume therapy

Patients on IMiDs The risk for thrombosis is greatest during the first few months of therapy

Patients on IMiDs Need for routine screening in the absence of symptoms